Skip to main content
Sailong Pharmaceutical Group Co., Ltd. logo

Sailong Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 002898 ISIN · CNE1000032S5 LEI · 8368004F5Y6BSB6US681 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,116 across all filing types
Latest filing 2024-08-28 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002898

About Sailong Pharmaceutical Group Co., Ltd.

https://www.sailong.cn

Sailong Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and marketing of high-end generic drugs and innovative formulations. The company maintains an integrated industrial chain encompassing active pharmaceutical ingredients (APIs) and finished dosage forms. Its product portfolio primarily targets therapeutic areas such as cardiovascular and cerebrovascular diseases, the digestive system, and anti-infective treatments. Key products include Monosialotetrahexosylganglioside Sodium Injection and Pantoprazole Sodium for Injection. The group emphasizes technological innovation and quality control to provide clinical solutions for complex medical conditions.

Recent filings

Filing Released Lang Actions
半年报监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of 赛隆药业集团股份有限公司 regarding their third meeting of the fourth session. It includes details about the meeting's convening, attendance, and resolutions passed, such as approval of the 2024 semi-annual report, reappointment of the audit firm, acceptance of subsidiary guarantees, and bank credit applications. The document does not contain the actual semi-annual report or financial statements but references other announcements where those reports are published. The document is short (1608 characters) and serves as an official meeting resolution announcement rather than a full financial or audit report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such announcements that do not fit other specific categories.
2024-08-28 Chinese
关于召开2024年第三次临时股东大会的通知
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2024 third extraordinary general meeting of shareholders for a company, including meeting date, voting procedures, agenda items, and proxy forms. It does not contain financial statements or results but rather informs shareholders about the meeting logistics and proposals to be voted on. This matches the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual General Meeting or similar shareholder meetings. The document length is under 5,000 characters and is a notice rather than a report or results announcement, so it is not a Report Publication Announcement (RPA).
2024-08-28 Chinese
2024年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "赛隆药业集团股份有限公司2024 年半年度报告全文" which translates to "Sailong Pharmaceutical Group Co., Ltd. 2024 Semi-Annual Report Full Text." It explicitly states it is a half-year report for the period January 1, 2024 to June 30, 2024. The content includes detailed financial data, management discussion and analysis, business overview, financial indicators, and other comprehensive information typical of an interim or quarterly report. The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement. There are no indications that this is merely an announcement or a certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-28 Chinese
2024年半年度财务报表
Regulatory Filings
2024-08-28 Chinese
董事会审计委员会关于公司计提减值准备事项合理性的说明
Audit Report / Information Classification · 95% confidence The document is a statement from the Board Audit Committee regarding the reasonableness of impairment provisions made by the company for the half-year period 2024. It references compliance with accounting standards and regulatory rules but does not contain detailed financial statements or comprehensive financial analysis. The document is short (476 characters) and serves as an explanatory note or certification rather than a full audit report or interim report. It is not an announcement of a report publication but a standalone statement about an accounting matter. Given these factors, the document fits best under Audit Report / Information (AR), as it relates to audit committee review and accounting policy application regarding impairment provisions. H1 2024
2024-08-28 Chinese
半年报董事会决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions passed at the fourth meeting of the fourth board of directors of Sailong Pharmaceutical Group Co., Ltd. It details the meeting date, attendance, and voting results on various proposals, including approval of the 2024 semi-annual report text and summary, changes to the company's business scope and articles of association, reappointment of the audit firm, acceptance of subsidiary guarantees, bank credit applications, and convening a shareholders' meeting. The document references other announcements and reports published separately on the CNINFO website, indicating this document itself is a board meeting resolution announcement rather than the full reports or financial statements. The content fits the category of Board/Management Information (MANG) as it concerns board meeting decisions and governance matters. The document length is short (1600 characters), consistent with an announcement rather than a full report.
2024-08-28 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.